2023 The 2nd Peptide and Nucleic Acid Drug Frontier Innovation Forum was successfully concluded in Chengdu on May 11-10! The forum gathered renowned scientists and entrepreneurs from the field of nucleic acid drugs, etc., who exchanged and shared the latest innovation results and research progress, which will strongly promote the further development of domestic nucleic acid drug industry. The forum will focus on target discovery, drug delivery and process scale-up to integrate resources and strengthen cooperation, creating an academic event for the whole industry chain of R&D for colleagues in the industry.
In the afternoon of April 11, Dr. Bing Feng, Senior Director of Oligonucleotide Division of Chinese Peptide company was invited to participate in this forum as a guest speaker to exchange academic ideas with experts and industry colleagues. He shared the in vitro and in vivo gene therapy drugs, CAR-T cell therapy, oligonucleotide drug types and their principles of action and briefly described the oligonucleotide drug delivery system, focusing on the mechanism of action of oligonucleotide CMC, the influence of oligonucleotide from chemical synthesis on its chemical characteristics, and how to control it in the production process. After the lecture, Dr. Feng Bing had a profound discussion with the experts and colleagues on site.
Introduction: Doctor of Science, Academy of Military Medical Sciences, Chief Engineer of China National Nucleic Acid Drug Engineering Center, sub-project leader of China National major project "Nucleic acid drug Innovative varieties Research and accurate modification and New packaged generic technology (2017ZX09303013)". Currently, he is the senior director of oligonucleotide Division of Zhongpeptide Biochemistry Co., LTD., mainly responsible for the construction of nucleic acid pharmaceutical platform, the establishment of oligonucleotide R&D and production team, as well as project management and production.
Chinese Peptide company was invited to participate in the 2nd Peptide and Nucleic Acid Drug Frontier Innovation Forum, during which Chinese Peptide company had a lively discussion with all the guests and industry colleagues, and introduced the latest research progress in the leading fields of peptide and nucleic acid CRDMO services.
Founded in 2001, Chinese peptide company is a trusted global integrated peptide/nucleic acid CRDMO partner. The production base of the Chinese peptide company and the new base in the United States will simultaneously ensure the product delivery of global customers, and provide global customers with a long-term stable supply chain of peptide apis, so as to better respond to the growing customer demand.
The peptide nucleic acid business is led by national and provincial experts. Nucleic acid project covers an area of 15 acres, construction area of about 26,700 square meters, after the completion of the project will form a 10-story ground building and three-story podium of modern drug research and development and production base. Through complementary and collaborative cooperation with Chinese peptide company, the Group will eventually build a global polypeptide/nucleic acid integrated whole industry chain platform, determined to help partners more compliant, safe and efficient development of patients in urgent need of drugs, and will also provide more comprehensive services for more pharmaceutical companies around the world.